Royalty Pharma (RPRX) EBIT (2019 - 2026)

Royalty Pharma (RPRX) has 8 years of EBIT data on file, last reported at $563.0 million in Q1 2026.

• For the quarter ending Q1 2026, EBIT rose 5.4% year-over-year to $563.0 million; the trailing twelve-month figure through Mar 2026 stood at $1.6 billion (down 16.42% YoY), and the FY2025 full-year result was $1.6 billion, up 20.66% from the prior year.
• EBIT advanced to $563.0 million in Q1 2026, from $388.4 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $735.1 million in Q3 2024 to a low of -$482.7 million in Q4 2022.
• A 5-year average of $306.7 million and a median of $361.5 million in 2024 frame the typical range for EBIT.
• Across the five-year window, EBIT slumped 414.6% in 2022 and soared 824.08% in 2025, its largest moves.
• Tracing RPRX's EBIT over 5 years: stood at -$482.7 million in 2022, then surged by 226.98% to $612.9 million in 2023, then slumped by 41.02% to $361.5 million in 2024, then climbed by 7.43% to $388.4 million in 2025, then surged by 44.97% to $563.0 million in 2026.
• Business Quant data shows RPRX's EBIT at $563.0 million in Q1 2026, $388.4 million in Q4 2025, and $427.2 million in Q3 2025.